News Lilly and Alder showcase latest migraine drug data Lilly and Alder take on the might of Novartis and Amgen
News FDA advisers back GW's Epidiolex for rare epilepsy UK firm's potential blockbuster on course for approval
News Novartis buys neurology biotech AveXis for $8.7bn Novartis has bought biotech AveXis for $8.7 billion, adding a potential gene therapy for the rare disease spinal muscular atrophy (SMA) to its pipeline.
News MS patient advocate hopes for pharma engagement after award Trishna Bharadia recognised for "tireless" campaigning
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
